Pathogenesis and Prevention of Hepatic Steatosis.

Hepatic steatosis is defined as intrahepatic fat of at least 5% of liver weight. Simple accumulation of triacylglycerols in the liver could be hepatoprotective; however, prolonged hepatic lipid storage may lead to liver metabolic dysfunction, inflammation, and advanced forms of nonalcoholic fatty liver disease. Nonalcoholic hepatic steatosis is associated with obesity, type 2 diabetes, and dyslipidemia. Several mechanisms are involved in the accumulation of intrahepatic fat, including increased flux of fatty acids to the liver, increased de novo lipogenesis, and/or reduced clearance through β-oxidation or very-low-density lipoprotein secretion. This article summarizes the mechanisms involved in the accumulation of triacylglycerols in the liver, the clinical implications, and the prevention of hepatic steatosis, with a focus on the role of mitochondrial function and lifestyle modifications.

[1]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[2]  G. Musso,et al.  Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). , 2009, Progress in lipid research.

[3]  William O Richards,et al.  Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. , 2010, Gastroenterology.

[4]  R. Rector,et al.  Reduced hepatic eNOS phosphorylation is associated with NAFLD and type 2 diabetes progression and is prevented by daily exercise in hyperphagic OLETF rats. , 2014, Journal of applied physiology.

[5]  Jian-Gao Fan,et al.  Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. , 2012, Hepatobiliary & pancreatic diseases international : HBPD INT.

[6]  J. Friedman,et al.  Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Rector,et al.  Metabolic inflexibility in skeletal muscle: a prelude to the cardiometabolic syndrome? , 2006, Journal of the cardiometabolic syndrome.

[8]  F. Booth,et al.  Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[9]  M. Ristow,et al.  Mitochondria and metabolic homeostasis. , 2013, Antioxidants & redox signaling.

[10]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[11]  S. Bellentani,et al.  Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). , 2009, Annals of hepatology.

[12]  S. Taylor-Robinson,et al.  Non-invasive means of measuring hepatic fat content. , 2008, World journal of gastroenterology.

[13]  McGinnis Jm,et al.  Actual causes of death in the United States. , 1993 .

[14]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[15]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[16]  F. Nassir,et al.  Role of Mitochondria in Nonalcoholic Fatty Liver Disease , 2014, International journal of molecular sciences.

[17]  T. Moran,et al.  Running wheel activity prevents hyperphagia and obesity in Otsuka long-evans Tokushima Fatty rats: role of hypothalamic signaling. , 2005, Endocrinology.

[18]  J. Dyck,et al.  Increased Hepatic CD36 Expression Contributes to Dyslipidemia Associated With Diet-Induced Obesity , 2007, Diabetes.

[19]  J. Stern,et al.  Spontaneous activity and adipose cellularity in the genetically obese Zucker rat (fafa). , 1977, Metabolism: clinical and experimental.

[20]  Frank W. Booth,et al.  Reduced physical activity and risk of chronic disease: the biology behind the consequences , 2008, European Journal of Applied Physiology.

[21]  Leah Hennings,et al.  A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[22]  J. Sallis,et al.  Physical Activity Recommendations, Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver Disease , 2011, The American Journal of Gastroenterology.

[23]  J. Browning,et al.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. , 2014, Gastroenterology.

[24]  J. Gerberding,et al.  Actual causes of death in the United States, 2000. , 2004, JAMA.

[25]  M. Yeh,et al.  The biopsied donor liver: Incorporating macrosteatosis into high‐risk donor assessment , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[26]  E. Ferrannini,et al.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.

[27]  J. Lavoie,et al.  Effects of ingesting a high-fat diet upon exercise-training cessation on fat accretion in the liver and adipose tissue of rats. , 2006, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[28]  A. Hamsten,et al.  Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. , 2007, The Journal of clinical endocrinology and metabolism.

[29]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[30]  S. Caldwell,et al.  The Natural History of Non-Alcoholic Fatty Liver Disease , 2010, Digestive Diseases.

[31]  F. Booth,et al.  Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. , 2010, Journal of Hepatology.

[32]  B. S. Mohammed,et al.  Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. , 2008, Gastroenterology.

[33]  F. Booth,et al.  Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[34]  A. Häkkinen,et al.  Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.

[35]  Z. Yao,et al.  ReviewRecent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion , 2010 .

[36]  F. Booth,et al.  Lack of exercise is a major cause of chronic diseases. , 2012, Comprehensive Physiology.

[37]  H. Ohdan,et al.  Ischemia–reperfusion injury in patients with fatty liver and the clinical impact of steatotic liver on hepatic surgery , 2014, Surgery Today.

[38]  J. Burnett,et al.  Genetic determinants of hepatic steatosis in man , 2011, Journal of Lipid Research.

[39]  F. Nassir,et al.  CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob/ob mice[S] , 2013, Journal of Lipid Research.

[40]  S. Sookoian,et al.  Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: Impact of liver methylation of the peroxisome proliferator–activated receptor γ coactivator 1α promoter , 2010, Hepatology.

[41]  M. Hellerstein,et al.  Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans Published, JLR Papers in Press, August 23, 2006. , 2006, Journal of Lipid Research.

[42]  S. Bellentani,et al.  Hepatology Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD) , 2009 .

[43]  J. Joh,et al.  Impact of hepatic macrovesicular and microvesicular steatosis on the postoperative liver functions after right hepatectomy in living donors. , 2012, Transplantation Proceedings.

[44]  F. Booth,et al.  Hepatic steatosis development with four weeks of physical inactivity in previously active, hyperphagic OLETF rats. , 2013, American journal of physiology. Regulatory, integrative and comparative physiology.

[45]  M. Beylot,et al.  Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. , 2003, Diabetes & metabolism.

[46]  O. Chazouilleres,et al.  Impact of steatosis on progression of fibrosis in patients with mild hepatitis C , 2005, Hepatology.

[47]  J. Schulz-Menger,et al.  Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects , 2011, Hepatology.

[48]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[49]  L. Adams,et al.  Recent concepts in non‐alcoholic fatty liver disease , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[50]  B. S. Mohammed,et al.  Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity , 2009, Proceedings of the National Academy of Sciences.

[51]  R. Rector,et al.  Does physical inactivity cause nonalcoholic fatty liver disease? , 2011, Journal of applied physiology.

[52]  Yoshimasa Kusano,et al.  Prevalence of fatty liver in Japanese children and relationship to obesity , 1995, Digestive Diseases and Sciences.

[53]  J. Kaprio,et al.  Increased physical activity decreases hepatic free fatty acid uptake: a study in human monozygotic twins , 2007, The Journal of physiology.

[54]  T. Muto,et al.  Regular physical activity and coronary risk factors in Japanese men. , 1998, Circulation.

[55]  Z. Halpern,et al.  Role of leisure‐time physical activity in nonalcoholic fatty liver disease: A population‐based study , 2008, Hepatology.

[56]  S. Harrison,et al.  Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection , 2010, Hepatology.

[57]  D. Lobo,et al.  Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. , 2004, Journal of hepatology.

[58]  A. Lonardo,et al.  Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. , 1996, Gastroenterology.

[59]  J. González‐Gallego,et al.  Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C , 2011, Gut.

[60]  G. O. Lignac [Actual causes of death]. , 1951, Nederlands tijdschrift voor geneeskunde.

[61]  F. Welty Hypobetalipoproteinemia and abetalipoproteinemia , 2014, Current opinion in lipidology.

[62]  J. Schwarz,et al.  Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. , 2003, The American journal of clinical nutrition.

[63]  J. Hirsch,et al.  Human fatty acid synthesis is reduced after the substitution of dietary starch for sugar. , 1998, The American journal of clinical nutrition.

[64]  A. Ascensão,et al.  Modulation of hepatic redox status and mitochondrial metabolism by exercise: therapeutic strategy for liver diseases. , 2013, Mitochondrion.

[65]  E. Hoffman,et al.  Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. , 2005, Cell metabolism.

[66]  Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing[S] , 2012, Journal of Lipid Research.

[67]  M. Connelly,et al.  Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile. , 2011, Human molecular genetics.

[68]  S. Burgess,et al.  Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. , 2011, Cell metabolism.

[69]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[70]  Gustav Schonfeld,et al.  Familial hypobetalipoproteinemia Published, JLR Papers in Press, March 16, 2003. DOI 10.1194/jlr.R300002-JLR200 , 2003, Journal of Lipid Research.

[71]  J. Barkin The Natural History of Nonalcoholic Fatty Liver Disease: A Population Based Cohort Study , 2006 .

[72]  B. Atshaves,et al.  Decreased Liver Fatty Acid Binding Capacity and Altered Liver Lipid Distribution in Mice Lacking the Liver Fatty Acid-binding Protein Gene* , 2003, Journal of Biological Chemistry.

[73]  S. Kennedy,et al.  Protection against Western diet–induced obesity and hepatic steatosis in liver fatty acid–binding protein knockout mice , 2006, Hepatology.

[74]  M. Nystrom,et al.  MRI steatosis grading: development and initial validation of a color mapping system. , 2012, AJR. American journal of roentgenology.

[75]  T. Lehtimäki,et al.  Liver and pancreatic fat content and metabolism in healthy monozygotic twins with discordant physical activity. , 2011, Journal of hepatology.

[76]  P. Blackman Actual causes of death in the United States. , 1994, JAMA.

[77]  B. Neuschwander‐Tetri Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites , 2010, Hepatology.

[78]  R. Rector,et al.  Modulating fibroblast growth factor 21 in hyperphagic OLETF rats with daily exercise and caloric restriction. , 2012, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[79]  J. Dyck,et al.  Increased Hepatic CD 36 Expression Contributes to Dyslipidemia Associated with Diet-Induced Obesity , 2007 .

[80]  B. S. Mohammed,et al.  Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. , 2008, Gastroenterology.

[81]  J. Cline,et al.  Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. , 2005, Gastroenterology.

[82]  F. Booth,et al.  Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats. , 2014, American journal of physiology. Endocrinology and metabolism.

[83]  L. Mâsse,et al.  Physical activity in the United States measured by accelerometer. , 2008, Medicine and science in sports and exercise.

[84]  Olga Ilkayeva,et al.  Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. , 2008, Cell metabolism.

[85]  F. Nassir,et al.  Role of mitochondria in alcoholic liver disease. , 2014, World journal of gastroenterology.

[86]  R. Ross,et al.  Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. , 2006, Gastroenterology.

[87]  N. Enomoto,et al.  Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[88]  D. Reeds,et al.  Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. , 2009, Gastroenterology.

[89]  Amalia Gastaldelli,et al.  Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.

[90]  J. George,et al.  Fitness versus fatness: Moving beyond weight loss in nonalcoholic fatty liver disease , 2010, Hepatology.

[91]  Chiadi E. Ndumele,et al.  Hepatic Steatosis, Obesity, and the Metabolic Syndrome Are Independently and Additively Associated With Increased Systemic Inflammation , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[92]  D. Harnois The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study , 2011 .

[93]  R. Gimeno,et al.  Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. , 2006, Gastroenterology.

[94]  Jiayin Yang,et al.  Impact of graft steatosis on the post-transplantation biliary complications for living donor liver transplant recipients in China. , 2012, Hepato-gastroenterology.

[95]  J. Ibdah,et al.  A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. , 1999, The New England journal of medicine.

[96]  Theresa A. Storm,et al.  Silencing of Hepatic Fatty Acid Transporter Protein 5 in Vivo Reverses Diet-induced Non-alcoholic Fatty Liver Disease and Improves Hyperglycemia* , 2008, Journal of Biological Chemistry.

[97]  M. Kay,et al.  FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. , 2010, American journal of physiology. Endocrinology and metabolism.

[98]  J. Friedman,et al.  Developmental origins of nonalcoholic fatty liver disease , 2014, Pediatric Research.

[99]  P. Nilsson,et al.  Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD , 2014, Scandinavian journal of gastroenterology.

[100]  D. Gomez,et al.  Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis , 2007, The British journal of surgery.

[101]  H. Kalbacher,et al.  De novo lipogenesis in health and disease. , 2014, Metabolism: Clinical and Experimental.

[102]  F. Hsu,et al.  Selective hepatic insulin resistance in a murine model heterozygous for a mitochondrial trifunctional protein defect , 2013, Hepatology.

[103]  F. Spener,et al.  Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake. , 1999, Biochimica et biophysica acta.

[104]  N. Johnson,et al.  Exercise and the Liver: Implications for Therapy in Fatty Liver Disorders , 2012, Seminars in Liver Disease.

[105]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.